Live Analyst Rating Changes 4942 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Ed Arce
WEST
Ed Arce
Wall Street Analyst
★★☆☆☆
#2033
on 13Foresight · ranked by our own returns
55%
Success Rate
+23.0%
Average Return
18 of 33 calls profitable · +6.7% vs benchmark
📈 Across the calls we could measure, roughly 55% of Ed Arce's ratings turned a profit when each position was held for 1 year — averaging +23.0% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

3 Buy 0 Hold 0 Sell
Ed's Stock Coverage 42 ratings · 2026-07-05
Company Date Position Consensus Price Target 1-Yr Return
TLPH
Talphera
Apr 30, 2026 BUY Buy
+340.4% avg upside
15 analysts
$3.00
180.35% Upside
-1.1%
MTVA
MetaVia
Sep 17, 2025 BUY Strong Buy
+1920.9% avg upside
13 analysts
$132.00
8818.89% Upside
-87.2%
UNCY
Unicycive Therapeutics
Apr 11, 2025 BUY Strong Buy
+828.5% avg upside
10 analysts
$75.00
1208.96% Upside
+21.0%
ARCT
Arcturus Therapeutics
Apr 11, 2025 BUY Buy
+303.6% avg upside
36 analysts
$60.00
724.08% Upside
-13.8%
AKBA
Akebia Therapeutics
Apr 04, 2025 BUY Strong Buy
+695.6% avg upside
16 analysts
$7.50
504.83% Upside
-22.0%
IVA
Inventiva
Apr 03, 2025 BUY Strong Buy
+310.9% avg upside
16 analysts
$13.00
232.49% Upside
-57.4%
GALT
Galectin Therapeutics
Apr 02, 2025 HOLD Strong Buy
+116.2% avg upside
8 analysts
+102.3%
ALGS
Aligos Therapeutics
Mar 31, 2025 BUY Strong Buy
+724.6% avg upside
11 analysts
$70.00
1152.24% Upside
-9.9%
ASMB
Assembly Biosciences
Mar 21, 2025 HOLD Strong Buy
+22.1% avg upside
10 analysts
+158.5%
ACXP
Acurx Pharmaceuticals
Mar 20, 2025 BUY Strong Buy
+4446.9% avg upside
4 analysts
$240.00
14900.10% Upside
-33.2%
PLRX
Pliant Therapeutics
Mar 18, 2025 HOLD Buy
+1804.7% avg upside
21 analysts
-24.3%
SGMT
Sagimet Biosciences, Inc. Class A
Mar 11, 2025 BUY Strong Buy
+270.5% avg upside
15 analysts
$32.00
320.47% Upside
+69.3%
MIRM
Mirum Pharmaceuticals
Feb 27, 2025 BUY Strong Buy
-6.9% avg upside
21 analysts
$72.00
42.75% Downside
+96.5%
MDGL
Madrigal Pharmaceuticals
Feb 27, 2025 BUY Strong Buy
-9.8% avg upside
31 analysts
$405.00
23.28% Downside
+28.7%
ARDX
Ardelyx
Feb 20, 2025 HOLD Strong Buy
+157.2% avg upside
21 analysts
$5.50
4.45% Upside
+0.2%
RARE
Ultragenyx Pharmaceutical
Feb 18, 2025 BUY Strong Buy
+98.5% avg upside
36 analysts
$95.00
183.88% Upside
-53.1%
ENTA
Enanta Pharmaceuticals
Feb 10, 2025 BUY Buy
+117.2% avg upside
17 analysts
$18.00
19.21% Upside
+188.4%
ABUS
Arbutus Biopharma
Jan 21, 2025 BUY Strong Buy
+81.4% avg upside
15 analysts
$5.00
2.77% Upside
+29.0%
NAMS
NewAmsterdam Pharma Company
Jan 14, 2025 BUY Strong Buy
+34.7% avg upside
18 analysts
$48.00
37.81% Upside
+34.8%
TVTX
Travere Therapeutics
Jan 14, 2025 BUY Strong Buy
-17.2% avg upside
22 analysts
$22.00
61.38% Downside
+69.5%
ITRMF
Iterum Therapeutics
Sep 10, 2024 BUY Buy
+14262.0% avg upside
5 analysts
$5.00
9919.98% Upside
·
AUPH
Aurinia Pharmaceuticals
Sep 05, 2024 BUY Strong Buy
-2.1% avg upside
12 analysts
$13.00
16.71% Downside
+79.5%
SYBX
Synlogic
Apr 24, 2024 HOLD Buy
+3333.9% avg upside
11 analysts
-38.0%
ZVSA
ZyVersa Therapeutics
Mar 26, 2024 BUY Buy
+84051.5% avg upside
2 analysts
$120.00
84051.48% Upside
·
VERA
Vera Therapeutics
Jan 25, 2024 BUY Strong Buy
+62.6% avg upside
19 analysts
$25.00
39.24% Downside
+34.0%
NBRVF
Nabriva Therapeutics
Mar 27, 2023 HOLD Strong Buy
+13374900.0% avg upside
9 analysts
·
GLMD
Galmed Pharmaceuticals
Mar 27, 2023 HOLD Buy
+4184.3% avg upside
13 analysts
-94.5%
SMMT
Summit Therapeutics
Dec 21, 2021 HOLD Strong Buy
+89.6% avg upside
27 analysts
+60.4%
ATXI
Avenue Therapeutics
Nov 29, 2021 HOLD Strong Buy
+5801.6% avg upside
4 analysts
·
FR:GNFT
Genfit
May 12, 2020 HOLD Strong Buy
+131.8% avg upside
5 analysts
·
FR:IVA
Inventiva
Mar 18, 2020 BUY Strong Buy
+418.7% avg upside
5 analysts
$12.00
250.88% Upside
·
COLL
Collegium Pharmaceutical
Feb 07, 2020 BUY Strong Buy
+13.8% avg upside
8 analysts
$31.00
16.31% Downside
-4.8%
VIVS
VivoSim Labs
Nov 11, 2019 HOLD Buy
+193.3% avg upside
5 analysts
+23.3%
SPRO
Spero Therapeutics
Aug 12, 2019 BUY Buy
+523.4% avg upside
12 analysts
$27.00
1127.18% Upside
+36.3%
TRVN
Trevena
Mar 14, 2019 HOLD Buy
+949900.0% avg upside
11 analysts
$1.25
83233.35% Upside
·
VKTX
Viking Therapeutics
Nov 28, 2017 BUY Strong Buy
+92.1% avg upside
31 analysts
$7.00
81.33% Downside
+304.3%
VXRT
Vaxart
Nov 06, 2017 HOLD Strong Buy
+1118.8% avg upside
8 analysts
-53.2%
NEPTF
Neptune Wellness Solutions
Jan 30, 2015 BUY Strong Buy
+400434400.1% avg upside
7 analysts
$5.00
499999900.01% Upside
·
BCRX
BioCryst
Jan 26, 2015 BUY Strong Buy
+87.4% avg upside
24 analysts
$20.00
103.16% Upside
-35.7%
ACUR
Acura Pharmaceuticals
Jan 09, 2015 BUY Buy
+333233.3% avg upside
2 analysts
$5.00
555455.61% Upside
·
XOMA
XOMA Royalty Corporation
Nov 14, 2014 BUY Buy
-47.9% avg upside
11 analysts
$9.00
79.15% Downside
-65.3%
AFFY
Affymax
Mar 19, 2013 SELL Hold
+942207.6% avg upside
3 analysts
$0.50
38361.44% Upside
+17.9%
🔒 37 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Ed Arce — Frequently Asked Questions
How accurate are Ed Arce's stock ratings?
Based on the calls 13Foresight could measure, about 55% of Ed's ratings were profitable over a one-year hold, with an average return of +23.0% per rating, or +6.7% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Ed ranked on 13Foresight?
Ed Arce is currently ranked #2033 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Ed cover?
Ed most recently has ratings on TLPH, MTVA, UNCY, ARCT, AKBA, IVA, GALT, ALGS, ASMB, ACXP, PLRX, SGMT and 30 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.